XML 48 R37.htm IDEA: XBRL DOCUMENT v3.19.1
Share-Based Payments - 2017 Share Incentive Plan (Details)
3 Months Ended
Jul. 26, 2017
shares
Mar. 31, 2019
USD ($)
item
$ / shares
shares
Mar. 31, 2018
USD ($)
Stock-Based Compensation Expense      
Share-based compensation expense | $   $ 1,907,000 $ 1,244,000
2017 Share Incentive Plan      
Options      
Outstanding at beginning of year (in shares)   2,398,425  
Granted (in shares)   2,211,100  
Forfeited (in shares)   (78,162)  
Outstanding at end of year (in shares)   4,531,363  
Vested and exercisable at end of year (in shares)   549,309  
Weighted average exercise price in $ per share      
Outstanding balance at beginning of year (in dollars per share) | $ / shares   $ 5.41  
Granted (in dollars per share) | $ / shares   1.90  
Forfeited (in dollars per share) | $ / shares   3.75  
Outstanding balance at end of year (in dollars per share) | $ / shares   3.73  
Vested and exercisable balance at end of year (in dollars per share) | $ / shares   $ 6.36  
Aggregate intrinsic value      
Aggregate intrinsic value, outstanding | $   $ 1,272,000  
2017 Share Incentive Plan | Stock Options      
Share-Based Payments      
Vesting period   10 years  
Fair Value Assumptions      
Expected term of options (in years)   6 years 1 month 6 days  
Dividend yield (as a percent)   0.00%  
Weighted-average remaining contractual life   9 years 4 months 24 days  
Stock-Based Compensation Expense      
Share-based compensation expense | $   $ 500,000 $ 400,000
Weighted-average grant date fair value (in dollars per share) | $ / shares   $ 1.08  
Unrecognized compensation expense      
Total unrecognized compensation related to unvested options | $   $ 7,300,000  
Recognition period   3 years 4 months 24 days  
2017 Share Incentive Plan | Stock Options | Minimum      
Fair Value Assumptions      
Expected volatility (as a percent)   61.40%  
Risk-free interest rate (as a percent)   2.47%  
Term of U.S. treasury securities used to estimate risk free interest rate   5 years  
2017 Share Incentive Plan | Stock Options | Maximum      
Fair Value Assumptions      
Expected volatility (as a percent)   61.60%  
Risk-free interest rate (as a percent)   2.58%  
Term of U.S. treasury securities used to estimate risk free interest rate   7 years  
2017 Share Incentive Plan | SARs      
Share-Based Payments      
Vesting period   10 years  
2017 Share Incentive Plan | Restricted Stock Units ("RSUs")      
Share-Based Payments      
Vesting period   4 years  
Expiration period if drug is not approved   2 years  
Stock-Based Compensation Expense      
Share-based compensation expense | $   $ 38,000  
Restricted Stock Units      
Restricted stock granted during the period   479,000  
Weighted average grant date fair value per share | $ / shares   $ 1.90  
Number of shares outstanding   479,000  
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting period, year one      
Restricted Stock Units      
Percentage that vests during the period   25.00%  
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting subject to FDA approval of NDA for lefamulin      
Stock-Based Compensation Expense      
Share-based compensation expense | $   $ 0  
Restricted Stock Units      
Aggregate number of shares granted under the plan   371,550  
Weighted average grant date fair value per share | $ / shares   $ 6.13  
Number of shares outstanding   383,550  
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval      
Restricted Stock Units      
Percentage that vests during the period   50.00%  
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval      
Restricted Stock Units      
Percentage that vests during the period   50.00%  
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting subject to FDA approval of NDA for lefamulin and CONTEPO      
Stock-Based Compensation Expense      
Share-based compensation expense | $   $ 0  
Restricted Stock Units      
Aggregate number of shares granted under the plan   35,600  
Weighted average grant date fair value per share | $ / shares   $ 2.56  
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Employees      
Share-Based Payments      
Number of vesting periods | item   3  
Vesting period   6 months  
Stock-Based Compensation Expense      
Share-based compensation expense | $   $ 268,000,000  
Weighted-average grant date fair value (in dollars per share) | $ / shares   $ 2.16  
Restricted Stock Units      
Aggregate number of shares granted under the plan   834,300  
Number of shares outstanding   780,300  
2017 Share Incentive Plan | Ordinary Shares      
Share-Based Payments      
Number of shares authorized 3,000,000    
Additional shares authorized 3,438,990    
Shares available for grant   7,087,042  
2017 Share Incentive Plan | Ordinary Shares | Minimum      
Share-Based Payments      
Annual increase, to be added on the first day of each fiscal year (in shares) 2,000,000    
Annual increase, to be added on the first day of each fiscal year (as a percent) 4.00%